Related Experiment Video

Updated: Feb 27, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K

Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014

Ginger Carls1, Johnny Huynh2, Edward Tuttle2

  • 1Analysis Group, Inc., Menlo Park, CA, USA. gingercarls@gmail.com.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|June 25, 2017
PubMed

Insights

Glycemic control in US adults with diabetes has not improved, with less than 51% meeting the glycated hemoglobin (HbA1c) target. Individualized targets also saw a decline, indicating a lack of progress in diabetes management.

Area of Science:

  • Endocrinology
  • Public Health
  • Clinical Medicine

Background:

  • Previous studies indicated stable glycated hemoglobin (HbA1c) levels above 50% for US adults with diabetes from 2003-2010.
  • The development of numerous diabetes medications over the past decade has not translated into improved glycemic control.
  • This study aimed to assess recent trends in HbA1c target achievement.

Purpose of the Study:

  • To compare recent (2011-2014) HbA1c target achievement data with earlier data.
  • To track progress in reaching a general HbA1c target of <7.0%.
  • To evaluate achievement of individualized glycemic targets based on age and comorbidities.

Main Methods:

  • Analysis of data from 2677 adults with self-reported diabetes from the National Health and Nutrition Examination Survey (NHANES) between 2007 and 2014.
  • Calculation of national estimates using NHANES complex sampling design weights.
  • Determination of the percentage of adults achieving HbA1c targets of <7% and individualized targets.

Main Results:

  • The proportion of adults with diabetes achieving an HbA1c <7.0% slightly decreased from 52.2% to 50.9% between recent survey waves.
  • Achievement of individualized glycemic targets declined from 69.8% to 63.8%.
  • The percentage of individuals with HbA1c >9.0% increased from 12.6% to 15.5%.

Conclusions:

  • Despite advancements in diabetes pharmacotherapy, there has been no improvement in the proportion of patients achieving glycemic control targets.
  • Glycemic control among US adults with diabetes remains suboptimal.
  • Trends in individualized target achievement mirrored those of the general target, varying by age and comorbidities.
Abstract

Keywords:
DiabetesGlycemic controlTrendsUnited States

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K
A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.5K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
672
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K